Atomwise, a leader in using artificial intelligence for small-molecule discovery, and Bridge Biotherapeutics, a clinical-stage biotech company, announced a research collaboration to launch up to 13 small-molecule programs across multiple therapeutic areas using structure-based AI technology for drug discovery.
Microsoft announced AI for Health, a new $40 million program which is part of the AI for Good initiative that will leverage artificial intelligence technology to “empower researchers and organizations addressing some of the world’s toughest challenges in health.”
Pharma companies from across the globe provide updates on their pipelines and business.
Over the last few years, there has appeared to be big interest on the part of biopharma in leveraging artificial intelligence (AI) and machine learning to improve trial design and speed up drug development. Another related category is digital therapeutics (DTx), which the Digital Therapeutics Alliance says, “deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage or treat a broad spectrum of physical, mental and behavioral conditions.”
Takeda Pharmaceutical has been on a tear over the past few weeks, striking deals to develop new therapies for various diseases. Now the Japan-based pharma powerhouse has announced a multi-year drug discovery deal with Charles River Laboratories.
PhoreMost entered into a multi-project drug discovery collaboration with Boehringer Ingelheim to develop innovative therapies for diseases with unsatisfactory treatments.
Biomedical engineers at the University of Minnesota conducted a first-of-its-kind study on molecular interactions.
Pharma and life sciences companies bolster their leadership teams and boards.
Three years after Novartis opened a $1 billion research & development facility in Shanghai, the company is shifting the focus of the site from drug discovery to commercial development.
Deep Genomics’ proprietary artificial intelligence-based drug discovery platform identified a novel treatment target and corresponding drug candidate for the rare and potentially life-threatening genetic disorder Wilson disease.